Amphastar Pharmaceuticals Inc (AMPH)
45.46
+0.91
(+2.04%)
USD |
NASDAQ |
Nov 22, 16:00
45.43
-0.03
(-0.07%)
After-Hours: 20:00
Amphastar Pharmaceuticals Enterprise Value: 2.532B for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 22, 2024 | 2.532B |
November 21, 2024 | 2.488B |
November 20, 2024 | 2.466B |
November 19, 2024 | 2.444B |
November 18, 2024 | 2.469B |
November 15, 2024 | 2.491B |
November 14, 2024 | 2.513B |
November 13, 2024 | 2.533B |
November 12, 2024 | 2.640B |
November 11, 2024 | 2.682B |
November 08, 2024 | 2.669B |
November 07, 2024 | 2.562B |
November 06, 2024 | 2.914B |
November 05, 2024 | 2.825B |
November 04, 2024 | 2.779B |
November 01, 2024 | 2.785B |
October 31, 2024 | 2.790B |
October 30, 2024 | 2.803B |
October 29, 2024 | 2.820B |
October 28, 2024 | 2.833B |
October 25, 2024 | 2.779B |
October 24, 2024 | 2.747B |
October 23, 2024 | 2.757B |
October 22, 2024 | 2.783B |
October 21, 2024 | 2.805B |
Date | Value |
---|---|
October 18, 2024 | 2.805B |
October 17, 2024 | 2.751B |
October 16, 2024 | 2.805B |
October 15, 2024 | 2.731B |
October 14, 2024 | 2.731B |
October 11, 2024 | 2.647B |
October 10, 2024 | 2.585B |
October 09, 2024 | 2.587B |
October 08, 2024 | 2.585B |
October 07, 2024 | 2.612B |
October 04, 2024 | 2.606B |
October 03, 2024 | 2.587B |
October 02, 2024 | 2.596B |
October 01, 2024 | 2.685B |
September 30, 2024 | 2.694B |
September 27, 2024 | 2.721B |
September 26, 2024 | 2.714B |
September 25, 2024 | 2.657B |
September 24, 2024 | 2.690B |
September 23, 2024 | 2.749B |
September 20, 2024 | 2.777B |
September 19, 2024 | 2.822B |
September 18, 2024 | 2.807B |
September 17, 2024 | 2.751B |
September 16, 2024 | 2.738B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
593.31M
Minimum
Mar 20 2020
3.514B
Maximum
Aug 08 2023
1.595B
Average
1.295B
Median
Mar 02 2022
Enterprise Value Benchmarks
Eli Lilly and Co | 737.78B |
BridgeBio Pharma Inc | 5.891B |
NovaBay Pharmaceuticals Inc | 2.608M |
Palatin Technologies Inc | 16.38M |
iBio Inc | 14.05M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 40.43M |
Revenue (Quarterly) | 191.21M |
Total Expenses (Quarterly) | 134.17M |
EPS Diluted (Quarterly) | 0.78 |
Gross Profit Margin (Quarterly) | 53.31% |
Profit Margin (Quarterly) | 21.14% |
Earnings Yield | 6.60% |
Operating Earnings Yield | 8.98% |
Normalized Earnings Yield | 6.599 |